{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:50:44Z","timestamp":1761630644991},"reference-count":79,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":914,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1111\/dth.12026","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T04:51:21Z","timestamp":1365051081000},"page":"120-134","source":"Crossref","is-referenced-by-count":10,"title":["Practical guidelines for the use of steroid-sparing agents in the treatment of chronic pruritus"],"prefix":"10.1155","volume":"26","author":[{"given":"Maren E. S.","family":"Cotes","sequence":"first","affiliation":[{"name":"Emory Department of Dermatology; Emory University; Atlanta; Georgia; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Swerlick","sequence":"additional","affiliation":[{"name":"Emory Department of Dermatology; Emory University; Atlanta; Georgia; USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,4,3]]},"reference":[{"issue":"10","key":"10.1111\/dth.12026-BIB0001|dth12026-cit-0001","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol"},{"issue":"12","key":"10.1111\/dth.12026-BIB0002|dth12026-cit-0002","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/archderm.139.12.1614","article-title":"French people and skin diseases: results of a survey using a representative sample","volume":"139","author":"Wolkenstein","year":"2003","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1111\/dth.12026-BIB0003|dth12026-cit-0003","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2340\/00015555-0641","article-title":"Measuring the prevalence of chronic itch in the general population: development and validation of a questionnaire for use in large-scale studies","volume":"89","author":"Matterne","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0004|dth12026-cit-0004","doi-asserted-by":"crossref","first-page":"674","DOI":"10.2340\/00015555-1159","article-title":"Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study","volume":"91","author":"Matterne","year":"2011","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1111\/dth.12026-BIB0005|dth12026-cit-0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1046\/j.1365-4362.2002.01460.x","article-title":"Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus","volume":"41","author":"Yosipovitch","year":"2002","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0006|dth12026-cit-0006","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/j.1365-2133.2004.06299.x","article-title":"Pruritus and psoriasis","volume":"151","author":"Szepietowski","year":"2004","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1111\/dth.12026-BIB0007|dth12026-cit-0007","first-page":"221","article-title":"Itching in patients suffering from psoriasis","volume":"10","author":"Szepietowski","year":"2002","journal-title":"Acta Dermatovenerol Croat"},{"issue":"4","key":"10.1111\/dth.12026-BIB0008|dth12026-cit-0008","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2340\/00015555-0662","article-title":"Epidemiology of itch: adding to the burden of skin morbidity","volume":"89","author":"Weisshaar","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0009|dth12026-cit-0009","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archderm.142.1.29","article-title":"Defining urticarial dermatitis: a subset of dermal hypersensitivity reaction pattern","volume":"142","author":"Kossard","year":"2006","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0010|dth12026-cit-0010","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1067\/mjd.2002.120908","article-title":"The clinical and histopathologic spectrum of \u201cdermal hypersensitivity reactions,\u201d a nonspecific histologic diagnosis that is not very useful in clinical practice, and the concept of a \u201cdermal hypersensitivity reaction pattern\u201d","volume":"47","author":"Fung","year":"2002","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1111\/dth.12026-BIB0011|dth12026-cit-0011","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1067\/mjd.2001.114738","article-title":"Balsam-related systemic contact dermatitis","volume":"45","author":"Salam","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1111\/dth.12026-BIB0012|dth12026-cit-0012","first-page":"137","article-title":"Salicylate intolerance: pathophysiology, clinical spectrum, diagnosis and treatment","volume":"105","author":"Baenkler","year":"2008","journal-title":"Dtsch Arztebl Int"},{"key":"10.1111\/dth.12026-BIB0013|dth12026-cit-0013","doi-asserted-by":"crossref","unstructured":"Fernando SL Clarke LR Salicylate intolerance: a masquerader of multiple adverse drug reactions BMJ Case Reports 2009 2009","DOI":"10.1136\/bcr.02.2009.1602"},{"key":"10.1111\/dth.12026-BIB0014|dth12026-cit-0014","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1440-1797.2012.01655.x","article-title":"Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance hemodialysis patients: a prospective crossover study","volume":"17","author":"Solak","year":"2012","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"10.1111\/dth.12026-BIB0015|dth12026-cit-0015","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1346-8138.2010.00830.x","article-title":"Brachioradial pruritus successfully treated with gabapentin","volume":"37","author":"Yilmaz","year":"2010","journal-title":"J Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0016|dth12026-cit-0016","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08860220802595476","article-title":"Gabapentin and uremic pruritus in hemodialysis patients","volume":"31","author":"Razeghi","year":"2009","journal-title":"Ren Fail"},{"issue":"4","key":"10.1111\/dth.12026-BIB0017|dth12026-cit-0017","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5055\/jom.2011.0073","article-title":"Analgesic efficacy of intravenous naloxone for the treatment of postoperative pruritus: a meta-analysis","volume":"7","author":"Murphy","year":"2011","journal-title":"J Opioid Manag"},{"issue":"4","key":"10.1111\/dth.12026-BIB0018|dth12026-cit-0018","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1111\/dth.12026-BIB0019|dth12026-cit-0019","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/0016-5085(92)90102-5","article-title":"A controlled trial of naloxone infusions for the pruritus of chronic cholestasis","volume":"102","author":"Bergasa","year":"1992","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1111\/dth.12026-BIB0020|dth12026-cit-0020","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"issue":"3 Pt 1","key":"10.1111\/dth.12026-BIB0021|dth12026-cit-0021","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0190-9622(99)70117-9","article-title":"Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study","volume":"41","author":"Bergasa","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1111\/dth.12026-BIB0022|dth12026-cit-0022","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.510270307","article-title":"Open-label trial of oral nalmefene therapy for the pruritus of cholestasis","volume":"27","author":"Bergasa","year":"1998","journal-title":"Hepatology"},{"issue":"2","key":"10.1111\/dth.12026-BIB0023|dth12026-cit-0023","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1111\/dth.12026-BIB0024|dth12026-cit-0024","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1346-8138.2007.00260.x","article-title":"Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide","volume":"34","author":"Lan","year":"2007","journal-title":"J Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0025|dth12026-cit-0025","first-page":"141","article-title":"Prurigo nodularis of Hyde treated with low-dose thalidomide","volume":"13","author":"Orlando","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"10.1111\/dth.12026-BIB0026|dth12026-cit-0026","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1111\/dth.12026-BIB0027|dth12026-cit-0027","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1529-8019.2005.00032.x","article-title":"Ultraviolet phototherapy for pruritus","volume":"18","author":"Rivard","year":"2005","journal-title":"Dermatol Ther"},{"issue":"Suppl 3","key":"10.1111\/dth.12026-BIB0028|dth12026-cit-0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1468-3083.2012.04520.x","article-title":"Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review","volume":"26","author":"Archier","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/dth.12026-BIB0029|dth12026-cit-0029","volume-title":"Radiation Volume 100\u2009D. A review of human carcinogens","author":"IARC","year":"2012"},{"key":"10.1111\/dth.12026-BIB0030|dth12026-cit-0030","volume-title":"Risk: why we fear the things we shouldn't and put ourselves in greater danger","author":"Gardner","year":"2009"},{"issue":"1","key":"10.1111\/dth.12026-BIB0031|dth12026-cit-0031","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/ar2373","article-title":"What do we know about communicating risk? A brief review and suggestion for contextualising serious, but rare, risk, and the example of cox-2 selective and non-selective NSAIDs","volume":"10","author":"Moore","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1111\/dth.12026-BIB0032|dth12026-cit-0032","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-4632.2009.04322.x","article-title":"Prevention and treatment of systemic glucocorticoid side effects","volume":"49","author":"Moghadam-Kia","year":"2010","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1111\/dth.12026-BIB0033|dth12026-cit-0033","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.clinthera.2011.09.009","article-title":"Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review","volume":"33","author":"Sarnes","year":"2011","journal-title":"Clin Ther"},{"issue":"1","key":"10.1111\/dth.12026-BIB0034|dth12026-cit-0034","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1345\/aph.1H219","article-title":"Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease","volume":"41","author":"Masunaga","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1111\/dth.12026-BIB0035|dth12026-cit-0035","doi-asserted-by":"crossref","first-page":"b2480","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"BMJ"},{"issue":"7","key":"10.1111\/dth.12026-BIB0036|dth12026-cit-0036","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/ajg.2009.745","article-title":"Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study","volume":"105","author":"Armstrong","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1111\/dth.12026-BIB0037|dth12026-cit-0037","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1111\/dth.12026-BIB0038|dth12026-cit-0038","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"issue":"9701","key":"10.1111\/dth.12026-BIB0039|dth12026-cit-0039","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/dth.12026-BIB0040|dth12026-cit-0040","first-page":"183","volume-title":"Comprehensive dermatologic drug therapy","author":"Badalamenti","year":"2007"},{"issue":"4","key":"10.1111\/dth.12026-BIB0041|dth12026-cit-0041","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1001\/archdermatol.2011.79","article-title":"Off-label use of azathioprine in dermatology: a systematic review","volume":"147","author":"Schram","year":"2011","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0042|dth12026-cit-0042","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.104.074815","article-title":"Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines","volume":"312","author":"Thomas","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1111\/dth.12026-BIB0043|dth12026-cit-0043","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/FTD.0b013e3181d12f19","article-title":"Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?","volume":"32","author":"Karner","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1111\/dth.12026-BIB0044|dth12026-cit-0044","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1542-3565(05)00697-X","article-title":"6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease","volume":"3","author":"Neurath","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0045|dth12026-cit-0045","first-page":"261","article-title":"Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro","volume":"15","author":"Rollinghoff","year":"1973","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"10.1111\/dth.12026-BIB0046|dth12026-cit-0046","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1111\/dth.12026-BIB0047|dth12026-cit-0047","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1016\/0006-2952(86)90623-4","article-title":"Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment","volume":"35","author":"Fairchild","year":"1986","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1111\/dth.12026-BIB0048|dth12026-cit-0048","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/01.fpc.0000114745.08559.db","article-title":"Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants","volume":"14","author":"Schaeffeler","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"5","key":"10.1111\/dth.12026-BIB0049|dth12026-cit-0049","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum","year":"1980","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1111\/dth.12026-BIB0050|dth12026-cit-0050","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s10620-006-9119-z","article-title":"Thiopurine methyltransferase activity in Spain: a study of 14,545 patients","volume":"52","author":"Gisbert","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1111\/dth.12026-BIB0051|dth12026-cit-0051","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","article-title":"Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease","volume":"35","author":"Chouchana","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1111\/dth.12026-BIB0052|dth12026-cit-0052","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1440-1746.2010.06254.x","article-title":"Azathioprine and allopurinol: a two-edged interaction","volume":"25","author":"Gearry","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0053|dth12026-cit-0053","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2036.2008.03782.x","article-title":"Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease","volume":"28","author":"Ansari","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1111\/dth.12026-BIB0054|dth12026-cit-0054","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/14740338.7.5.607","article-title":"Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol","volume":"7","author":"Leong","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1111\/dth.12026-BIB0055|dth12026-cit-0055","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1445-5994.2005.00904.x","article-title":"Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice","volume":"35","author":"Gearry","year":"2005","journal-title":"Intern Med J"},{"issue":"4","key":"10.1111\/dth.12026-BIB0056|dth12026-cit-0056","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1111\/dth.12026-BIB0057|dth12026-cit-0057","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2012.07.001","article-title":"Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring","volume":"68","author":"Caufield","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0058|dth12026-cit-0058","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mjd.2001.109296","article-title":"Thioguanine for refractory psoriasis: a 4-year experience","volume":"44","author":"Mason","year":"2001","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1111\/dth.12026-BIB0059|dth12026-cit-0059","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-111-8-641","article-title":"6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity","volume":"111","author":"Present","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1111\/dth.12026-BIB0060|dth12026-cit-0060","first-page":"197","volume-title":"Comprehensive dermatologic drug therapy","author":"Perlis","year":"2007"},{"issue":"2","key":"10.1111\/dth.12026-BIB0061|dth12026-cit-0061","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-3083.1991.tb03746.x","article-title":"Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion","volume":"33","author":"Eugui","year":"1991","journal-title":"Scand J Immunol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0062|dth12026-cit-0062","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-3083.1991.tb03747.x","article-title":"Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice","volume":"33","author":"Eugui","year":"1991","journal-title":"Scand J Immunol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0063|dth12026-cit-0063","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1681\/ASN.V131277","article-title":"Gastrointestinal complications of transplant immunosuppression","volume":"13","author":"Helderman","year":"2002","journal-title":"J Am Soc Nephrol: JASN"},{"issue":"1","key":"10.1111\/dth.12026-BIB0064|dth12026-cit-0064","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jaad.2012.07.003","article-title":"Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases","volume":"68","author":"Sokumbi","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0065|dth12026-cit-0065","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jaad.2008.08.049","article-title":"Mycophenolate mofetil in dermatology","volume":"60","author":"Orvis","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0066|dth12026-cit-0066","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2133.2002.04875.x","article-title":"Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil","volume":"147","author":"Schanz","year":"2002","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1111\/dth.12026-BIB0067|dth12026-cit-0067","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/09546630410020154","article-title":"Mycophenolate mofetil in pyoderma gangrenosum","volume":"15","author":"Lee","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/dth.12026-BIB0068|dth12026-cit-0068","first-page":"163","volume-title":"Comprehensive dermatologic drug therapy","author":"Callen","year":"2007"},{"issue":"2","key":"10.1111\/dth.12026-BIB0069|dth12026-cit-0069","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0070|dth12026-cit-0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1468-3083.2009.03351.x","article-title":"Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults","volume":"24","author":"Lyakhovitsky","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0071|dth12026-cit-0071","first-page":"377","article-title":"Methotrexate in autoimmune urticaria","volume":"70","author":"Godse","year":"2004","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0072|dth12026-cit-0072","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2009.09538.x","article-title":"Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria","volume":"162","author":"Perez","year":"2010","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0073|dth12026-cit-0073","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1046\/j.1365-2133.2001.04330.x","article-title":"Methotrexate-responsive chronic idiopathic urticaria: a report of two cases","volume":"145","author":"Gach","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12026-BIB0074|dth12026-cit-0074","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","article-title":"The mechanism of action of FK-506 and cyclosporin A","volume":"696","author":"Wiederrecht","year":"1993","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"10.1111\/dth.12026-BIB0075|dth12026-cit-0075","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jaad.2011.10.033","article-title":"Open-label, pilot study examining sequential therapy with oral tacrolimus and topical tacrolimus for severe atopic dermatitis","volume":"67","author":"Keaney","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1111\/dth.12026-BIB0076|dth12026-cit-0076","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaad.2004.09.023","article-title":"Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study","volume":"52","author":"Kessel","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"3 Pt 1","key":"10.1111\/dth.12026-BIB0077|dth12026-cit-0077","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jaad.2004.11.022","article-title":"Infliximab in the treatment of moderate to severe atopic dermatitis","volume":"52","author":"Jacobi","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1111\/dth.12026-BIB0078|dth12026-cit-0078","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2008.02.007","article-title":"Alefacept for moderate to severe atopic dermatitis: a pilot study in adults","volume":"58","author":"Moul","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1111\/dth.12026-BIB0079|dth12026-cit-0079","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaad.2008.04.006","article-title":"A pilot quality-of-life instrument for pruritus","volume":"59","author":"Desai","year":"2008","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12026","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12026\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:59:58Z","timestamp":1671818398000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12026"}},"subtitle":["Management of chronic pruritus"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,3]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12026","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}